Actively Recruiting
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
Led by AHS Cancer Control Alberta · Updated on 2025-06-27
24
Participants Needed
1
Research Sites
210 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to prospectively evaluate the feasibility of SBRT for the management of synchronous oligo metastatic liver metastases from colorectal cancers.
CONDITIONS
Official Title
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Able to provide written informed consent
- 1 to 5 liver lesions with a maximum size of 5 cm for any single lesion, all limited to one lobe of the liver
- Liver lesion identified within 3 months of primary cancer diagnosis and deemed suitable for SBRT with curative intent by Multi-Disciplinary Tumor Board (MDT)
- Plan for surgical removal of the primary tumor with curative intent
- Patients with liver metastases and potentially resectable or ablatable lung metastases are eligible
- Colon cancer patients who have already had surgery to remove the primary colon lesion are eligible
- Able and willing to follow the study protocol including completing health-related quality of life questionnaires
- Women of childbearing potential must have a negative pregnancy test at screening
- Women must not be breastfeeding
- Male patients must agree not to donate sperm during the study
You will not qualify if you...
- Presence of metastases outside the liver, except potentially resectable lung metastases
- Not a suitable candidate for liver surgery
- Not a suitable candidate for SBRT
- History of cancer in the past 5 years, except for basal cell carcinoma
- Previous surgery or ablation for liver lesions
- Planned simultaneous surgery to remove primary tumor and liver metastases
- Pregnancy
- Severe liver disease classified as Child-Pugh C or documented cirrhosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
Research Team
A
Aswin Abraham
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here